Table 1. Baseline Characteristics of A5127 Study Participants.
| All | ADV arm | TDF arm | |
|---|---|---|---|
| Number of subjects | 52 | 25 | 27 |
| Age: median in years | 41 | 47 | 40 |
| Male, n (%) | 48 (92%) | 24 (96%) | 24 (89%) |
| Caucasian, n (%) | 29 (56%) | 14 (56%) | 15 (56%) |
| African American, n (%) | 17 (33%) | 8 (32%) | 9 (33%) |
| Prior IV drug use, n (%) | 7 (13%) | 1 (4%) | 6 (22%) |
| Serum HBV DNA log10 mean copies/mL* | 9.16 ± 1.54 | 8.85 ± 1.88 | 9.45 ± 1.1 |
| HBeAg positive, n (%) | 41 (79%) | 20 (80%) | 23 (85%) |
| 3TC experienced, n (%) | 47 (94) | 24 (96%) | 25 (93%) |
| CPT score < 7, n (%) | 51 (98%) | 25 (100%) | 26 (96%) |
| ALT (median IU/mL) | 52 | 63 | 45 |
| ALT ≤ ULN n (%) | 29 (56%) | 13 (52%) | 16 (59%) |
| AST (median IU/mL) | 42 | 46 | 38 |
| Hematocrit % (median) | 42.4 | 44.2 | 42.3 |
| White cell count (median cells × 109/L) | 5.2 | 5.4 | 5.1 |
| CD4 (median cells × 106/L) | 467 | 486 | 422 |
| CD4 count > 200 cells × 106/L n(%) | 48 (92%) | 23 (92%) | 25 (93%) |
| Bilirubin (median mg/dL) | 0.6 | 0.6 | 0.5 |
| Albumin (median g/dL) | 4.1 | 4.2 | 4.0 |
| Creatinine (mean ± SD mg/dL) | 0.94 ± 0.2 | 0.96 ± 0.2 | 0.93 ± 0.2 |
| Phosphorus (mean ±± SD mg/dL) | 3.18 ± 0.6 | 3.15 ± 0.5 | 3.2 ± 0.7 |
*
Baseline HBV DNA was defined as the mean of the log measurements prior to entry and at entry.